SMN2 and proximal spinal muscular atrophy: ZPR1 upregulates SMN2 protein transcription and promotes SMN protein activation for myelin regeneration, and upregulation of ZPR1 expression to increase SMN levels is a viable therapeutic target for the development of new approaches to SMA treatment (10, 11).